Thomas Wynn spent 26 years at the NIH, wrapping up recently as a senior investigator and recognized expert on immunology and fibrosis. And he cites NIH chief Francis Collins as a key factor in his decision to leave the National Institute of Allergy and Infectious Diseases and head up early discovery in Pfizer’s inflammation and immunology unit.
But in a good way.
During Collins’ lengthy tenure at the NIH, says Wynn, the federal research institute shifted focus to become much more directly involved with drug developers. For Wynn, that meant two active projects with Pfizer where he was able to get a much better look at the pharma giant’s research operations — and they got to know him as well.
“He’s really ushered in a really good collaboration with Big Pharma and biotech,” Wynn tells me about Collins. The NIH always did a lot of great basic science, but in the past there wasn’t the same kind of push to translate that science into drugs.
But that’s changed now. Pfizer’s been undergoing some changes as well, says Wynn, with an eye to melding the way the discovery, preclinical and clinical operations operate.
“We have a pretty big portfolio of early things we’re looking at,” he says, with better models for evaluating early targets. Fibrosis is just one of the spotlights, he adds, ticking off other specialties like atopic dermatitis, psoriasis, ulcerative colitis and lupus.
Wynn says he’s excited about making the migration into Big Pharma circles, something we’ve been seeing a lot of as academic and government scientists are drawn into the big research hubs where the largest R&D operations have been concentrating their forces. There have been multiple examples of that, with plenty more to come, as top investigators are recruited throughout biopharma. Wynn’s particularly happy about moving into Cambridge, MA, with a lab in the pharma giant’s new Kendall Square digs.
In his new job, he can work with a wide variety of investigators in Pfizer, and throughout the hub.
“That’s my major motivation for coming here; doing collaborations in drug development,” says Wynn. “I can do it at a much higher level. At Pfizer there are experts in all these areas. As a basic scientist, I have lots of great ideas, I may have 20 great ideas. With the experts here, I can have meetings and say, of those 20, which are the best? Which targets can I develop a small molecule with.”
It’s that one molecule that will make all the difference.
Says Wynn: “I think if I could get even one really big drug that made a big impact on the health of patients I would look back and feel proud of what I did.”
More Peer Review
⇨ Shaun Coughlin is handing in his old title as director of UC San Francisco’s Cardiovascular Research Center in favor of a new job running the cardio group for the Novartis Institute for Biomedical Research. Coughlin has been at UCSF for 33 years, but he’s returning to some familiar stomping grounds. Coughlin got his undergraduate degree at MIT, his MD at Harvard Med and did his postdoc work at Mass General.
⇨ Teva R&D exec Spyridon “Spyros” Papapetropoulos is joining Cavion as its new R&D chief. The little biotech has been working on new drugs that modulate the T-type calcium channel (Cav3) for the treatment of neurological diseases.
⇨ Cambridge, MA-based Jounce Therapeutics has picked Ariad vet Hugh Cole as its new chief business officer and head of corporate development. Cole is credited with doing nine deals for Ariad.
⇨ CrownBio’s President/CSO and COO, Alex Wu and Bing Zhu, are both retiring. Wu, a cofounder and had previously served as CEO. A new addition to the crew includes Yangzhou Wang as senior vice president of global operations.
⇨ Cerecor CEO Uli Hacksell, who joined after getting bumped at Acadia, said will now step aside from the helm, but stay on as chairman of the board.
⇨ ZS Pharma’s CEO Robert Alexander and CSO Adam Tomasi have jumped ship to Allakos. Alexander has sidestepped into the CEO role at the California-based company while Tomasi moves to the CFO position.
⇨ Array Biopharma has announced Curtis Oltmans as General Counsel. Oltmans previous gigs include Novo Nordisk and Eli Lilly.
⇨ Bryan Irving has leaped from CytomX to become the SVP of research at Five Prime Therapeutics.
⇨ CFO Andrew Singer will be leaving his post at Epizyme “to pursue other business opportunities.”
⇨ Avenue Therapeutics has a new VP of finance: Joseph Vazzano, who hails from Intercept.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.Free Subscription